|
|
||||||||



*
Institute of General Pathology, University of Verona, Verona, Italy; and
International Center for Genetic Engineering and Biotechnology, Trieste, Italy;
Department of Medicine, University College London, Rayne Institute, London, United Kingdom; and
§
Central Laboratory of The Netherlands Red Cross Blood Transfusion Service, and Laboratory for Experimental and Clinical Immunology, University of Amsterdam, Amsterdam, The Netherlands
This paper deals with the mechanisms of activation of NADPH oxidase investigated using EBV-transformed human B lymphoblastoid cell lines (B cells) from normal subjects and from patients affected by X-linked chronic granulomatous disease (CGD). The results reported are as follows. 1) In normal B cells, the NADPH oxidase components p67phox, p40phox, p22phox, and gp91phox were less expressed than in polymorphonuclear neutrophils. 2) In normal B cells stimulated with PMA, p47phox, p67phox, and p40phox translocated to the membranes as occurs in polymorphonuclear neutrophils. 3) In CGD, B cells expressing p22phox in the absence of gp91phox, p47phox, p67phox, and p40phox did not translocate to the membranes after stimulation with PMA. 4) In PMA-stimulated B cells from an X91+ CGD patient in which p22phox was normally expressed and gp91phox was present but lacked five amino acids, translocation of p47phox to the membranes was unaffected, but p67phox and p40phox were poorly translocated, and the production of O2- was greatly reduced with respect to that by normal B cells. Taken together, these findings indicate that 1) a low expression of some NADPH oxidase components may represent the molecular basis of the low production of O2- in B lymphocytes; 2) the cytosolic components of NADPH oxidase cannot bind to p22phox on the membranes in the absence of gp91phox; 3) p47phox can translocate to the membranes independently of p67phox and p40phox; and 4) gp91phox may have a role in mediating and/or stabilizing the binding of p67phox and p40phox to the membranes of activated cells.
This article has been cited by other articles:
![]() |
M. Luengo-Blanco, C. Prando, J. Bustamante, W. C. Aragao-Filho, P. V. S. Pereira, J. Rehder, C. Padden, J.-L. Casanova, P. E. Newburger, and A. Condino-Neto Essential role of nuclear factor-{kappa}B for NADPH oxidase activity in normal and anhidrotic ectodermal dysplasia leukocytes Blood, August 15, 2008; 112(4): 1453 - 1460. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Donini, S. Fontana, G. Savoldi, W. Vermi, L. Tassone, F. Gentili, E. Zenaro, D. Ferrari, L. D. Notarangelo, F. Porta, et al. G-CSF treatment of severe congenital neutropenia reverses neutropenia but does not correct the underlying functional deficiency of the neutrophil in defending against microorganisms Blood, June 1, 2007; 109(11): 4716 - 4723. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. J. Bleesing, M. M. Souto-Carneiro, W. J. Savage, M. R. Brown, C. Martinez, S. Yavuz, S. Brenner, R. M. Siegel, M. E. Horwitz, P. E. Lipsky, et al. Patients with Chronic Granulomatous Disease Have a Reduced Peripheral Blood Memory B Cell Compartment. J. Immunol., June 1, 2006; 176(11): 7096 - 7103. [Abstract] [Full Text] [PDF] |
||||
![]() |
X. J. Li, D. Grunwald, J. Mathieu, F. Morel, and M.-J. Stasia Crucial Role of Two Potential Cytosolic Regions of Nox2, 191TSSTKTIRRS200 and 484DESQANHFAVHHDEEKD500, on NADPH Oxidase Activation J. Biol. Chem., April 15, 2005; 280(15): 14962 - 14973. [Abstract] [Full Text] [PDF] |
||||
![]() |
U. Bayraktutan, L. Blayney, and A. M. Shah Molecular Characterization and Localization of the NAD(P)H Oxidase Components gp91-phox and p22-phox in Endothelial Cells Arterioscler Thromb Vasc Biol, August 1, 2000; 20(8): 1903 - 1911. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |